Expanding Horizons for Treatment of Early-Stage Lung Cancer

Lung cancer remains the leading cause of cancer-related death worldwide.(1) Even in the context of early-stage disease, survival among patients with lung cancer lags behind that among patients with other common cancers, such as colon, breast, and prostate cancer. The likelihood of 5-year survival remains modest,(2) with patients having both local or regional relapse and metastatic relapse. Although surgery with curative intent remains the foundation for management of early-stage lung cancer, these data speak to the urgent need for improvements in systemic control. With the advent of targeted therapies directed against mutant oncoproteins and immune-checkpoint inhibitors to promote host antitumor . . .

Automated summary

Lung cancer is the leading cause of cancer-related death worldwide. Patients with early-stage lung cancer have lower survival rates compared to other common cancers, highlighting the need for improved systemic control methods such as targeted therapies against mutant oncoproteins and immune checkpoint inhibitors.